RESUMO
Abstract This study assessed the anthelminthic feed additive albendazole effect on the main indicators of the quality of sheep meat obtained from infected and deworming animals. A total of 20 heads of Akzhaik meat and wool sheep (i.e. 2 years of age, of different sex) were used in a 20-day experiment and 2 groups of 10 heads were formed (n = 4). The sheep were fed with the basic diet (i.e. control, group CON), without adding anything, and the second group was fed the basic diet orally with the addition of a dose of 1.2 g / head (an experimental group). At the end of the experiment, a control slaughter was carried out from each group in order to study the biochemical composition of meat and its quality. The anthelmintic feed additive albendazole did not have a significant effect on the indicators (organoleptic and physicochemical) of meat quality (P> 0.04). However, the ratio of fat and ash in the meat of the control group has differences in indicators and is reduced by 24.81% and 0.03%, respectively. The drug had a significant effect on the biological value of meat in the experimental group, where there is a higher content of essential amino acids (P = 0.06), nonessential (P = 0.05) concentrations in comparison with the CON groups. The results obtained show that the meat of the experimental groups of sheep, when using the anthelminthic feed additive albendazole, did not have a significant effect on organoleptic parameters, but significantly positively influenced the metabolism, live weight gain and biological value of meat.
Resumo Este estudo avaliou o efeito do aditivo anti-helmíntico albendazol sobre os principais indicadores de qualidade da carne ovina obtida de animais infectados e desparasitados. Um total de 20 cabeças de carne Akzhaik e ovelhas de lã (ou seja, 2 anos de idade, de sexo diferente) foi usado em um experimento de 20 dias e dois grupos de 10 cabeças foram formados (n = 4). As ovelhas foram alimentadas com dieta básica (ou seja, controle, grupo CON), sem adicionar nada, e o segundo grupo foi alimentado com dieta básica por via oral com a adição de uma dose de 1,2 g / cabeça (um grupo experimental). Ao final do experimento, foi realizado um abate controle de cada grupo para estudar a composição bioquímica da carne e sua qualidade. O aditivo anti-helmíntico albendazol não teve efeito significativo sobre os indicadores (organolépticos e físico-químicos) de qualidade da carne (P > 0,04). No entanto, a proporção de gordura e cinzas na carne do grupo de controle tem diferenças nos indicadores e é reduzida em 24,81% e 0,03%, respectivamente. A droga teve efeito significativo sobre o valor biológico da carne no grupo experimental, onde há maior teor de aminoácidos essenciais (P = 0,06), concentrações não essenciais (P = 0,05) em comparação com os grupos CON. Os resultados obtidos mostram que a carne dos grupos experimentais de ovinos, ao utilizar o aditivo anti-helmíntico albendazol, não teve efeito significativo nos parâmetros organolépticos, mas influenciou positivamente de forma significativa no metabolismo, ganho de peso vivo e valor biológico da carne.
Assuntos
Animais , Ração Animal/análise , Anti-Helmínticos , Ovinos , Albendazol , Dieta/veterinária , Carne/análiseRESUMO
La hidatidosis o equinococosis quística es una zoonosis parasitaria endémica causada por el estadio larvario del cestode Echinococcus granulosus. El hígado y el pulmón son los órganos con afección más frecuente. Su ubicación subcutánea es una entidad rara, poco descrita, y por ende un reto diagnóstico. Describimos el caso de una mujer, de 18 años de edad, procedente de un área endémica, que presentó un quiste hidatídico primario supraclavicular.
Hydatid disease or cystic echinococcosis is an endemic parasitic zoonosis caused by the larval stage of the cestode Echinococcus granulosus, the liver and lung being the most frequently affected organs. Its subcutaneous location is a rare entity, little described, and therefore a diagnostic challenge. We describe the case of an 18-year-old woman from an endemic area who presented with a primary supraclavicular hydatid cyst.
Assuntos
Humanos , Feminino , Adolescente , Equinococose/cirurgia , Equinococose/diagnóstico , Equinococose/tratamento farmacológico , Albendazol/uso terapêutico , Biópsia por Agulha Fina , Echinococcus granulosus , Anticestoides/uso terapêuticoRESUMO
La hidatidosis pancreática representa el 0,2-0,6 % de los casos, siendo la población pediátrica la de mayor riesgo. Las lesiones suelen localizarse en cabeza del páncreas (50-58 %); la localización en cuerpo y cola del páncreas se encuentra en el 24-34 % y el 19 %, respectivamente. Dada la posibilidad de complicaciones, suele realizarse tratamiento quirúrgico. Se sugiriere indicar albendazol antes y después del acto quirúrgico por los riesgos de ruptura y diseminación de los protoescólices. Se presenta el caso de una niña de 5 años de edad con dolor abdominal progresivo y lesión quística en páncreas compatible con hidatidosis en la ultrasonografía. En la tomografía computada se observa compresión de la vía biliar. La hemoaglutinación indirecta fue negativa. Presentó elevación de la bilirrubina total, con franco predominio de bilirrubina directa, y aumento de enzimas hepáticas. Se realizó laparotomía exploradora, colecistectomía y destechamiento del quiste. Evolucionó favorablemente, continuó con albendazol durante 3 meses luego de la cirugía.
Pancreatic echinococcosis accounts for 0.20.6% of cases, with the pediatric population being at a higher risk. Most commonly, pancreatic lesions occur in the head of the pancreas (5058%); and in the body and tail in 2434% and 19% of cases, respectively. Given the potential complications, surgery is usually performed. Albendazole is recommended before and after the surgery due to the risks for rupture and dissemination of protoscolices. Here we describe the case of a 5-year-old girl with progressive abdominal pain and cystic lesion in the pancreas compatible with echinococcosis in the ultrasound. The computed tomography showed bile duct compression. Indirect hemagglutination was negative. She had elevated total bilirubin, with a clear predominance of direct bilirubin, and high liver enzymes. Exploratory laparotomy, cholecystectomy, and unroofing of the cyst were performed. The patient had a favorable course and continued with albendazole for 3 months after the surgery.
Assuntos
Humanos , Feminino , Pré-Escolar , Pancreatopatias/cirurgia , Pancreatopatias/complicações , Pancreatopatias/diagnóstico , Equinococose/cirurgia , Equinococose/complicações , Equinococose/diagnóstico , Pâncreas , Albendazol/uso terapêutico , AbdomeRESUMO
Echinococcosis is a zoonotic parasitic disease caused by infection with Echinococcus species. As the drug of first choice for treatment of echinococcosis, albendazole suffers from problems of large doses and remarkable adverse reactions in clinical therapy. Development of novel drugs against echinococcosis is of urgent need. Recently, great advances have been achieved in the research on traditional Chinese medicine for treatment of echinococcosis. This review summarizes the progress of researches on traditional Chinese medicine for treatment of echinococcosis, aiming to provide insights into development of anti-echinococcosis drugs.
Assuntos
Animais , Humanos , Medicina Tradicional Chinesa , Equinococose/parasitologia , Albendazol/uso terapêutico , Zoonoses , Echinococcus multilocularisRESUMO
Primary splenic hydatid cyst is a rare entity even in endemic areas. In most cases it presents asymptomatically being diagnosed by imaging findings. Treatment is multimodal and individualized, being surgical treatment the one that allows an integral solution of the disease. Conventional surgery continues to be the "Gold standard" in its approach. We present the case of a patient with this condition and the resolution approached by the surgical team.
O cisto hidatides esplénico primário é uma entidade rara mesmo em áreas endémicas. Na maioria dos casos apresenta-se de forma assintomática, sendo diagnosticada através de resultados de imagem. O tratamento é multimodal e individualizado, com um tratamento cirúrgico que proporciona uma solução abrangente para a condição. A cirurgia convencional continua a ser a abordagem "padrão de ouro". Apresentamos o caso de um paciente com esta condição e a resolução abordada pela equipa cirúrgica.
El quiste hidático primario esplénico es una entidad poco frecuente aún en áreas endémicas. Se presenta en la mayoría de los casos de forma asintomática, siendo diagnosticado por hallazgo imagenológico. El tratamiento es multimodal e individualizado, siendo el tratamiento quirúrgico el que permite una solución integral de la dolencia. La cirugía convencional sigue siendo el "Gold estándar" en su abordaje. Presentamos el caso de una paciente con esta afección y la resolución abordada por el equipo de cirugía.
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Esplenopatias/cirurgia , Equinococose Hepática/cirurgia , Esplenectomia , Esplenopatias/diagnóstico , Albendazol/uso terapêutico , Equinococose Hepática/diagnóstico , Anti-Helmínticos/uso terapêuticoRESUMO
The purpose of this work was to elaborate a diagnosis of the dissolution test in Africa in comparison with Brazil, evaluating the dissolution profile of low solubility drugs such as albendazole, ibuprofen, furosemide, glibenclamide, hydrochlorothiazide and carvedilol to ascertain their quality. The dissolution profiles were evaluated by utilizing the United States Pharmacopeia (USP). The glibenclamide medicine was evaluated according to the Food and Drug Administration (FDA), while a dissolution method was developed for the carvedilol medicine. A filter selection test for all the drugs showed that cannula is suitable for all, except for carvedilol, which is centrifuged. The various brands of Nigerian and Brazilian medicines tested showed some statistical differences. The suitable conditions that allowed the dissolution of carvedilol to be determined were the USP type II apparatus at 75 rpm containing 900 mL of acetate buffer, pH 4.5. The results of the dissolution test showed that out of the 17 different brands of Brazilian medicines and 17 different products from Nigeria, 94.12% and 58.82% passed respectively
O objetivo deste trabalho foi elaborar um diagnóstico do teste de dissolução na África em comparação ao Brasil, avaliando o perfil de dissolução de medicamentos de baixa solubilidade como albendazol, ibuprofeno, furosemida, glibenclamida, hidroclorotiazida e carvedilol para verificar sua qualidade.Os perfis de dissolução foram avaliados utilizando a Farmacopeia dos Estados Unidos (USP). O medicamento glibenclamida foi avaliado de acordo com a Food and Drug Administration (FDA), enquanto um método de dissolução foi desenvolvido para o medicamento carvedilol.Um teste de seleção de filtro para todos os medicamentos mostrou que a cânula é adequada para todos, exceto para o carvedilol, que é centrifugado. As diversas marcas de medicamentos Nigerianos e Brasileiros testadas apresentaram algumas diferenças estatísticas. As condições adequadas que permitiram a determinação da dissolução do carvedilol foram o aparelho USP tipo II a 75 rpm contendo 900 mL de tampão acetato, pH 4,5. Os resultados do teste de dissolução mostraram que das 17 diferentes marcas de medicamentos brasileiros e 17 diferentes produtos da Nigéria, 94,12% e 58,82% foram aprovados, respectivamente
Assuntos
Solubilidade , Brasil/etnologia , Preparações Farmacêuticas/análise , África/etnologia , Dissolução , United States Food and Drug Administration , Albendazol/farmacologia , Ibuprofeno , Carvedilol/farmacologia , Furosemida/farmacologia , Métodos , Acetatos/efeitos adversosRESUMO
La mayor proporción de individuos afectados por la parasitosis intestinal corresponde a la población infantil, debido a su inmadurez inmunológica y poco desarrollo de hábitos higiénicos y la práctica de jugar con tierra. Los estudios realizados en zonas rurales a nivel internacional sobre prevalencia de parasitosis intestinales en niños, reportan cifras que varían entre el 30 y 90 %. En los países afectados, entre los que figura notablemente Ecuador, las infecciones parasitarias intestinales están estrechamente relacionadas a los procesos de desarrollo económico y social. Ochenta y un escolares de zonas semirrurales (20%) cumplieron con los criterios diagnósticos de parasitosis intestinal. La Blastocystis sp. (10%), fue la especie parasitaria más comúnmente encontrada, en segundo lugar E. nana (3,7%) y en tercer lugar Complejo Entamoeba (2,5%). Específicamente en la población infantil de zonas semirrurales no se han realizado estudios de pesquisaje recientes en el contexto ecuatoriano y se ignora qué consecuencias pudo tener la pandemia de COVID-19 para la prevalencia de estas infecciones. Se desarrolló una investigación sobre los antecedentes y prevalencia de parasitosis intestinal en escolares de zonas semirrurales de Ecuador a fin de aportar información empírica al respecto(AU)
The largest proportion of individuals affected by intestinal parasitosis corresponds to the child population, due to their immunological immaturity and little development of hygienic habits and the practice of playing with dirt. - Studies carried out in rural areas at the international level on the prevalence of intestinal parasites in children, report figures that vary between 30% and 90%. In the affected countries, including notably Ecuador, intestinal parasitic infections are closely related to the processes of economic and social development. Eighty-one schoolchildren from semi-rural areas (20%) met the diagnostic criteria for intestinal parasitosis. The Blastocystis sp. (10%), was the most commonly found parasitic species, in second place E. nana (3.7%) and in third place Entamoeba Complex (2.5%). Specifically, in the child population of semi-rural areas, no recent screening studies have been carried out in the Ecuadorian context and the consequences the COVID-19 pandemic could have had on the prevalence of these infections are unknown. An investigation was developed on the background and prevalence of intestinal parasitosis in schoolchildren from semi-rural areas of Ecuador in order to provide empirical information in this regard(AU)
Assuntos
Humanos , Masculino , Feminino , Criança , Estudantes , Criança , Infecções por Blastocystis , Entamoeba , Enteropatias Parasitárias , Doenças Parasitárias , Condições Sociais , Albendazol , Zona Rural , Higiene , HábitosRESUMO
RESUMEN La hidatidosis cervical es una enfermedad poco frecuente aun en áreas endémicas. Suele presentarse como una lesión quística indolora de lenta evolución. Se presenta un caso clínico de una paciente femenina de 19 años con una lesión quística en el compartimento cervical central, inicialmente interpretada como un quiste tirogloso. El diagnóstico debe ser sospechado ante epidemiología compatible, el método de imágenes de elección es la ecografía. En localizaciones extrahepáticas los métodos serológicos tienen baja sensibilidad. El tratamiento de elección es la cirugía, realizando tratamiento perioperatorio con albendazol. Debe manipularse el quiste con cuidado para evitar su rotura y el derrame de contenido líquido, por riesgo de reacción anafiláctica, recurrencia e hidatidosis múltiple. En pacientes con alto riesgo quirúrgico puede optarse por realizar tratamiento médico con albendazol.
ABSTRACT Cervical echinococcosis is a rare disease, even in endemic areas. The lesions usually present as painless slow-growing cystic lesion. We report the case of a 19-year-old female patient with a cystic lesion in the central cervical region that was initially interpreted as a thyroglossal duct cyst. The diagnosis should be suspected when the epidemiology is consistent, and ultrasound is the imaging method of choice. The sensitivity of serologic tests is low in extrahepatic locations. Surgery is the treatment of choice and the administration of albendalzole before surgery is indicated. The cyst must be handled with care to avoid rupture and leakage of cyst contents, which can cause anaphylaxis, recurrence and multiple echinococcosis. In patients with high surgical risk, medical treatment alone may be the option.
Assuntos
Humanos , Feminino , Adulto , Cisto Tireoglosso , Cistos/diagnóstico por imagem , Equinococose/diagnóstico por imagem , Testes Sorológicos , Albendazol , Doença , Sensibilidade e Especificidade , Diagnóstico , Equinococose , AnafilaxiaRESUMO
Resumen Se presenta el caso de una niña de 8 años, procedente de la Amazonia peruana, con una presentación atípica de una toxocariasis. El cuadro clínico, de un mes de evolución, fue caracterizado por dolor abdominal crónico, palidez y geofagia, asociado a una masa abdominal y linfoadenopatías generalizadas. No hubo sintomatología respiratoria, dérmica, ocular o neurológica. En el hemograma se encontró una anemia y eosinofilia periférica acentuada y una eosinofilia moderada en el aspirado medular. El diagnóstico fUe confirmado por serología por el método de enzimoinmunoanálisis (ELISA), que mostró la presencia de anticuerpos anti-Toxocara de tipo IgG e IgM. Se administró tratamiento con albendazol 400 mg al día, durante cinco días, con una evolución favorable.
Abstract We present the case of an 8-year-old girl with an atypical presentation of toxocariasis, from the Peruvian Amazon. A month ago, the clinical presentation was characterized by the presence of abdominal pain, paleness and geophagia, associated with an abdominal mass and generalized lymphadenopathy. There were no respiratory, dermal, ocular or neurological symptoms. Marked peripheral eosinophilia was found in the blood count, and moderate eosinophilia in the spinal cord aspírate. The diagnosis was confirmed by serology with the enzyme-linked immunosorbent assay (ELISA), which showed the presence of IgG and IgM anti- Toxocara antibodies. Treatment with albendazole 400 mg once daily was administered for five days with favorable evolution.
Assuntos
Humanos , Animais , Feminino , Criança , Toxocaríase/diagnóstico , Toxocaríase/tratamento farmacológico , Eosinofilia/diagnóstico , Eosinofilia/tratamento farmacológico , Toxocara , Ensaio de Imunoadsorção Enzimática , Anticorpos Anti-Helmínticos , Albendazol/uso terapêuticoRESUMO
Resumen La trichostrongylosis es una zoonosis de rara ocurrencia causada por nematodos intestinales, favorecida por el consumo de vegetales crudos o agua contaminada con larvas infectantes de Trichostrongylus spp. En 2015, se registró un brote familiar transmitido por alimentos en una zona rural de Valdivia, afectando a una mujer de 51 años de edad y su pareja e hija de 56 y 12 años; respectivamente. Solo la mujer adulta, el caso índice, presentó síntomas como diarrea, dolor abdominal, astenia y náuseas. Los pacientes eliminaron huevos de Trichostrongylidae gen. sp. en sus deposiciones, identificándose en dos de ellos, adultos de Trichostrongylus colubriformis. Tuvieron una buena respuesta a albendazol. En Chile, se han registrado prevalencias de infección de 0,1 a 3,5%, incluyendo un total de 93 casos diagnosticados entre las provincias de Concepción y Llanquihue.
Abstract Trichostrongylosis is a rare occurrence zoonosis caused by intestinal nematodes, favored by the consumption of raw vegetables or water contaminated with infective larvae of Trichostrongylus spp. In 2015, a family outbreak of foodborne disease was registered in a rural zone of Valdivia, affecting to 51-year-old woman and her 56-year-old partner and her 12-year-old daughter. Only the adult woman, the index case, presented symptoms such as diarrhea, abdominal pain, asthenia, and nausea. The patients revealed Trichostrongylidae gen. sp. eggs in their stools, identifying Trichostrongylus colubriformis adults in two of them. They had a good response to treatment with albendazol. In Chile, 0.1 to 3.5% prevalence of infection has been reported, including a total of 93 cases recorded between the provinces of Concepción and Llanquihue.
Assuntos
Humanos , Animais , Feminino , Criança , Pessoa de Meia-Idade , Tricostrongilose/diagnóstico , Tricostrongilose/tratamento farmacológico , Trichostrongylus , Tricostrongilose/epidemiologia , Zoonoses , Albendazol/uso terapêutico , Surtos de Doenças , Fezes/parasitologia , Doenças Transmitidas por AlimentosRESUMO
El síndrome DRESS es una reacción adversa dermatológica que puede presentarse debido a diversos medicamentos, y constituye uno de los diagnósticos más importantes por encima del síndrome de Stevens-Johnson. Se trata de un caso relacionado con una reacción adversa de muy baja frecuencia, que está documentada en la literatura científica, a varios medicamentos, entre ellos la fenitoína. Por lo mencionado, la publicación de estos casos resulta escasa y limitada. Las principales preocupaciones del paciente relacionadas con su cuadro clínico radicaban en el gran compromiso cutáneo que lo llevó a hospitalización, dolor e incomodidad, por el cual recurrió al manejo tópico generalizado con vaselina. Los hallazgos clínicos relevantes fueron: eosinofilia severa, ulceraciones cutáneas, hepatitis química y fiebre. Con los hallazgos del cuadro clínico y la evaluación de la escala RegiSCAR se hace el diagnóstico de síndrome DRESS inducido por fenitoína. Se suspende la fenitoína, se inicia levetiracetam y se administran corticosteroides y acetaminofén con evolución favorable. (AU)
DRESS syndrome is a dermatological adverse reaction can occur due to various medications, being one of the most important diagnoses above Steven-Johnson syndrome. This is a case related to a very low frequency adverse reaction that is documented in the scientific literature to several medicines among those, the phenytoin. Therefore, the publication of these cases is scarce and limited. The main concerns of the patients related to their clinical picture were due to the great cutaneous compromise that lead to hospitalization, pain and discomfort for which they resorted to generalized topical management with vaseline (petrolatum). Relevant clinical findings were severe eosinophilia, skin ulcerations, chemical hepatitis and fever. With clinical picture findings and evaluation of the RegiSCAR scale, the diagnosis of Phenytoin-induced DRESS syndrome is made. Phenytoin is discontinued, levetiracetam is started and corticosteroids and acetaminophen are administrated with favorable evolution. (AU)
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Fenitoína/efeitos adversos , Síndrome de Hipersensibilidade a Medicamentos/diagnóstico , Vaselina/uso terapêutico , Fenitoína/administração & dosagem , Albendazol/administração & dosagem , Corticosteroides/administração & dosagem , Eosinofilia/etiologia , Exantema/diagnóstico , Levetiracetam/administração & dosagem , Acetaminofen/uso terapêuticoAssuntos
Humanos , Masculino , Criança , Larva Migrans/diagnóstico , Dermatopatias Vesiculobolhosas/diagnóstico , Larva Migrans/tratamento farmacológico , Albendazol/uso terapêutico , Dermatopatias Vesiculobolhosas/tratamento farmacológico , Ancylostoma/crescimento & desenvolvimento , Anti-Helmínticos/uso terapêuticoRESUMO
O objetivo deste artigo foi comparar o uso da ivermectina e do albendazol em pacientes transplantados e relatar os respectivos sucessos terapêuticos nessa população. Foram analisados artigos que abordassem relatos de casos publicados nos últimos 4 anos no PubMed® relacionando os descritores "transplante de órgãos", "estrongiloidíase" e "tratamento". Foram encontrados e analisados dez relatos de caso que abordaram a estrongiloidíase em situa- ção pós-transplante contemplando 13 indivíduos. Desses, cinco (38,5%) utilizaram ambos os medicamentos, dos quais quatro (80%) se curaram, tendo recebido albendazol e ivermectina por via subcutânea (50%) ou albendazol e ivermectina por vias oral/ subcutânea (50%). O paciente que morreu recebeu albendazol e ivermectina por via subcutânea. Sete (53,8%) indivíduos utiliza- ram apenas ivermectina, dos quais três (42,8%) se curaram tendo recebido o medicamento oral (dois pacientes) ou subcutâneo (um paciente); dois (28,6%) morreram recebendo o medicamento via oral, dois (28,6%) usaram profilaticamente via oral e apenas um não manifestou sintomas. Apenas um (7,7%) indivíduo utilizou somente albendazol via oral tendo sobrevivido à infecção. A uti- lização combinada dos medicamentos ivermectina e albendazol parece ter efeito positivo no tratamento da estrongiloidíase. A administração da ivermectina por via subcutânea apresentou resultados promissores, contudo estudos controlados de siner- gia medicamentosa e vias de administração devem ser realizados para efetiva avaliação.
The objective of this article was to compare the use of ivermec- tin and albendazole in transplanted patients and to report the respective therapeutic successes in this population.Articles ad- dressing case reports published in the last 4 years in the PubMed relating the descriptors "organ transplantation", "strongyloidia- sis", and "treatment" were analyzed. Ten case reports addres- sing strongyloidiasis in a post-transplant situation, covering 13 individuals, were found and analyzed. Of these, five (38.5%) used both drugs of which 4 (80%) were cured having received subcu- taneous albendazole and ivermectin (50%) or oral/subcutaneous albendazole and ivermectin (50%). The patient who died received subcutaneous albenzadole and ivermectin. Seven (53.8%) indi- viduals used only ivermectin, of which three (42.8%) were cured having received the oral (2/3) or subcutaneous (1/3) medication, two (28.6%) died receiving the oral medication, and two (28.6%) used oral medication prophylactically, and only one did not show symptoms. Only one (7.7%) individual used only oral albenzadole and survived the infection. The combined use of the drugs iver- mectin and albendazole seems to have a positive effect on the treatment of strongyloidiasis. The administration of subcuta- neous Ivermectin has shown promising results; however, con- trolled studies of drug synergy and administration routes shall be performed for effective evaluation.
Assuntos
Humanos , Estrongiloidíase/tratamento farmacológico , Ivermectina/uso terapêutico , Albendazol/uso terapêutico , Transplantados , Anti-Helmínticos/uso terapêutico , Estrongiloidíase/prevenção & controle , Administração Oral , Transplante de Medula Óssea , Transplante de Coração , Transplante de Rim , Transplante de Pâncreas , Evolução Fatal , Quimioterapia Combinada , Injeções SubcutâneasRESUMO
Abstract Trichinellosis is a zoonosis results from eating raw or semi-cooked meat of infected animals. Medicinal plants have been used lately as alternatives and/or combined therapies to resolve some drawbacks of the current regimens. This work analyzed the effect of albendazole monotherapy on Trichinella spiralis experimental infection (group A), in comparison to P. granatum and amygdalin extracts +cobalamin (group B), plus its combination with albendazole (group C). The study revealed that the extracts alone or combined with albendazole had an inferior effect to albendazole monotherapy regarding number of adult worms (40.83 ±3.82, 18.67 ±1.86 and 16.83 ±2.32, respectively). However, their effect was more obvious in muscle phase combined with albendazole, achieving the lower number of larvae/mL tissue homogenate (22.33 ±3.27 in comparison to 39.67 ±2.58 achieved by albendazole monotherapy). The extracts exerted a significant immunomodulatory effect by reducing the local CD4+ expression in the intestine as well as in muscle phase (1.15 ±0.25 and 3.80 ±0.65 in comparison to 4.97 ±0.37 and 12.20 ±0.87 with albendazole monotherapy, respectively). So, these extracts improved the therapeutic efficacy of albendazole, specifically in muscle phase and counteracted the inflammatory reaction caused by albendazole monotherapy, thus extensively alleviating the resulting myositis.
Resumo Trichinellosis é uma zoonose resultante da ingestão de carne crua ou semicozida de animais infectados. As plantas medicinais têm sido usadas, ultimamente, como alternativas e/ou terapias combinadas, para resolver algumas desvantagens dos regimes atuais. Este trabalho analisou o efeito da monoterapia albendazole na infecção experimental por Trichinella spiralis (grupo A), em comparação com extratos de P. granatum e amígdalina +cobalamina (grupo B), além de sua combinação com albendazol (grupo C). O estudo revelou que os extratos sozinho ou combinado com albendazol teve efeito inferior à monoterapia albendazol em relação ao número de vermes adultos (40,83 ±3,82, 18,67 ±1,86 e 16,83 ±2,32, respectivamente). No entanto, seu efeito foi mais óbvio na fase muscular combinado com o albendazol, alcançando o menor número de larvas/mL homogeneizado de tecido (22,33 ±3,27 em comparação com 39,67 ±2,58 obtidos pela monoterapia albendazol). Os extratos exerceram um efeito imunomodulatório significativo, ao reduzir a expressão local CD4+ no intestino, bem como na fase muscular (1,15 ±0,25 e 3,80 ±0,65 em comparação com 4,97 ±0,37 e 12,20 ±0,87 com monoterapia albendazol, respectivamente). Assim, esses extratos melhoraram a eficácia terapêutica do albendazol, especificamente na fase muscular e neutralizaram a reação inflamatória causada pela monoterapia albendazol, aliviando extensivamente a miosite resultante.
Assuntos
Animais , Triquinelose/tratamento farmacológico , Triquinelose/veterinária , Trichinella spiralis , Punica granatum , Amigdalina , Miosite/veterinária , Vitamina B 12 , Extratos Vegetais , Albendazol , Modelos Animais de Doenças , LarvaRESUMO
Abstract An evaluation was made of the effect of anthelmintic treatments on the performance of Simmental X Nellore crossbred calves before and after weaning. To this end, the calves were divided into three groups: (1) treated monthly with a low efficacy anthelmintic drug, ivermectin; (2) treated monthly with a highly effective anthelmintic drug, albendazole; and (3) untreated control group. All the groups in this experiment showed an average fecal egg count of less than 400 eggs per gram (EPG), and no clinical signs of parasitic gastroenteritis. The blood variables were within the normal range and no calf presented anemia. In most of the samplings, mean EPGs were significantly lower (P<0.05) in the group treated with albendazole. The calves received dietary supplementation before and after weaning, which enabled them to gain weight in every month of the experiment and reach a body weight of about 250 kg on the last sampling date, before turning one year old. The anthelmintic treatments did not affect body weight gain, leading to the conclusion that, when fed with suitable dietary supplements, Simmental X Nellore crossbred calves are not affected by gastrointestinal nematode parasites acquired by grazing.
Resumo O objetivo do experimento foi avaliar o efeito de tratamentos anti-helmínticos no desempenho de bezerros Simental x Nelore antes e após o desmame. Os bezerros foram alocados em três grupos: (1) tratado mensalmente com anti-helmínticos de baixa eficácia, ivermectina; (2) tratado mensalmente com anti-helmíntico de alta eficácia, albendazol e (3) controle não tratado. A média das contagens de ovos de nematoides durante o experimento foi inferior a 400 ovos por grama (OPG) em todos os grupos sem manifestação clínica de gastroenterite parasitária. As variáveis sanguíneas mantiveram-se dentro dos limites de normalidade e nenhum bezerro apresentou anemia. Na maioria das coletas, as médias de OPG foram significativamente inferiores (P<0,05) no grupo tratado com albendazol. Os bezerros receberam suplementação antes e depois do desmame, o que lhes permitiu ganhar peso em todos os meses do experimento, atingindo peso corporal em torno de 250 kg, ao final do experimento, antes de completarem um ano de idade. Não houve efeito dos tratamentos anti-helmínticos no ganho em peso, o que permitiu concluir que bezerros Nelore x Simental não são afetados pelo parasitismo por nematoides gastrintestinais sob condições de pastejo, quando devidamente suplementados com concentrado.
Assuntos
Animais , Masculino , Feminino , Bovinos , Ivermectina/administração & dosagem , Albendazol/administração & dosagem , Doenças dos Bovinos/tratamento farmacológico , Gastroenteropatias/veterinária , Anti-Helmínticos/administração & dosagem , Infecções por Nematoides/veterinária , Contagem de Ovos de Parasitas/veterinária , Fezes/parasitologia , Gastroenteropatias/parasitologia , Gastroenteropatias/tratamento farmacológico , Infecções por Nematoides/parasitologia , Infecções por Nematoides/tratamento farmacológicoRESUMO
BACKGROUND It was previously demonstrated that CMC-20, a nitazoxanide and N-methyl-1H-benzimidazole hybrid molecule, had higher in vitro activity against Giardia intestinalis WB strain than metronidazole and albendazole and similar to nitazoxanide. OBJETIVES To evaluate the in vitro activity of CMC-20 against G. intestinalis strains with different susceptibility/resistance to albendazole and nitazoxanide and evaluate its effect on the distribution of parasite cytoskeletal proteins and its in vivo giardicidal activity. METHODS CMC-20 activity was tested against two isolates from patients with chronic and acute giardiasis, an experimentally induced albendazole resistant strain and a nitazoxanide resistant clinical isolate. CMC-20 effect on the distribution of parasite cytoskeletal proteins was analysed by indirect immunofluorescence and its activity was evaluated in a murine model of giardiasis. FINDINGS CMC-20 showed broad activity against susceptible and resistant strains to albendazole and nitaxozanide. It affected the parasite microtubule reservoir and triggered the parasite encystation. In this process, alpha-7.2 giardin co-localised with CWP-1 protein. CMC-20 reduced the infection time and cyst load in feces of G. muris infected mice similar to albendazole. MAIN CONCLUSIONS The in vitro and in vivo giardicidal activity of CMC-20 suggests its potential use in the treatment of giardiasis.
Assuntos
Humanos , Animais , Camundongos , Tiazóis/farmacologia , Albendazol/farmacologia , Giardia lamblia/efeitos dos fármacos , Proteínas do Citoesqueleto/efeitos dos fármacos , Antiprotozoários/farmacologia , Tiazóis/química , Fatores de Tempo , Albendazol/química , Técnica Indireta de Fluorescência para Anticorpo , Testes de Sensibilidade Parasitária , Antiprotozoários/químicaRESUMO
BACKGROUND It was previously demonstrated that CMC-20, a nitazoxanide and N-methyl-1H-benzimidazole hybrid molecule, had higher in vitro activity against Giardia intestinalis WB strain than metronidazole and albendazole and similar to nitazoxanide. OBJETIVES To evaluate the in vitro activity of CMC-20 against G. intestinalis strains with different susceptibility/resistance to albendazole and nitazoxanide and evaluate its effect on the distribution of parasite cytoskeletal proteins and its in vivo giardicidal activity. METHODS CMC-20 activity was tested against two isolates from patients with chronic and acute giardiasis, an experimentally induced albendazole resistant strain and a nitazoxanide resistant clinical isolate. CMC-20 effect on the distribution of parasite cytoskeletal proteins was analysed by indirect immunofluorescence and its activity was evaluated in a murine model of giardiasis. FINDINGS CMC-20 showed broad activity against susceptible and resistant strains to albendazole and nitaxozanide. It affected the parasite microtubule reservoir and triggered the parasite encystation. In this process, alpha-7.2 giardin co-localised with CWP-1 protein. CMC-20 reduced the infection time and cyst load in feces of G. muris infected mice similar to albendazole. MAIN CONCLUSIONS The in vitro and in vivo giardicidal activity of CMC-20 suggests its potential use in the treatment of giardiasis.
Assuntos
Humanos , Animais , Camundongos , Tiazóis/farmacologia , Albendazol/farmacologia , Giardia lamblia/efeitos dos fármacos , Proteínas do Citoesqueleto/efeitos dos fármacos , Antiprotozoários/farmacologia , Tiazóis/química , Fatores de Tempo , Albendazol/química , Técnica Indireta de Fluorescência para Anticorpo , Testes de Sensibilidade Parasitária , Antiprotozoários/químicaAssuntos
Humanos , Masculino , Adulto , Derrame Pleural/etiologia , Teníase/complicações , Ascaridíase , Albendazol , EosinofiliaRESUMO
Abstract Hepatopulmonary hydatidosis in young children is a rare and atypical presentation of Echinococcus granulosus infection. We report the first case of cystic echinococcosis caused by a microvariant of E. granulosus sensu stricto. Chemotherapy and systemic corticoids were administered before curative surgery was performed. Recurrence was not observed for more than 24 months of follow-up.